Nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer

Korean Journal of Internal Medicine

Volumn 26, Issue 3, 2011, Pages 304-313

  Kim, Young Sun ^a   Lee, Hye Lim ^a   Lee, Ki Bum ^b   Park, Joo Hun ^a   Chung, Wou Young ^a   Lee, Keu Sung ^a   Sheen, Seung Soo ^a   Park, Kwang Joo ^a   Hwang, Sung Chul ^a  

^a Departments of Pulmonary and Critical Care Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

GA binding protein transcription factor; Lung neoplasms; Peroxiredoxins; Sulfiredoxin

Indexed keywords

CAMPTOTHECIN; CYSTEINE SULFHYDRYL; PEROXIREDOXIN 1; PEROXIREDOXIN 3; REACTIVE OXYGEN METABOLITE; REGULATOR PROTEIN; SULFIREDOXIN; THIOL DERIVATIVE; THIOREDOXIN; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CARCINOMA CELL; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; ENZYME ACTIVE SITE; ENZYME INACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; LUNG ALVEOLUS EPITHELIUM; LUNG PARENCHYMA; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MINK; NF-E2-RELATED FACTOR 2; OXIDOREDUCTASES ACTING ON SULFUR GROUP DONORS; PEROXIREDOXIN III; PEROXIREDOXINS; PROGNOSIS; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 80054864969     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2011.26.3.304     Document Type: Article

References (29)

1. Rhee SG. Cell signaling: H2O2, a necessary evil for cell signaling. Science 2006;312:1882-1883.
2. Chowdhury I, Mo Y, Gao L, Kazi A, Fisher AB, Feinstein SI. Oxidant stress stimulates expression of the human peroxiredoxin 6 gene by a transcriptional mechanism involving an antioxidant response element. Free Radic Biol Med 2009;46:146-153.
3. Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem 1998;273:6297-6302.
4. Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH. 2-Cys per-oxiredoxin function in intracellular signal transduction: therapeutic implications. Trends Mol Med 2005;11:571-578.
5. Chang TS, Jeong W, Woo HA, Lee SM, Park S, Rhee SG. Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J Biol Chem 2004;279:50994-51001.
6. Lei K, Townsend DM, Tew KD. Protein cysteine sulfinic acid reductase (sulfiredoxin) as a regulator of cell proliferation and drug response. Oncogene 2008;27:4877-4887.
7. Rhee SG, Jeong W, Chang TS, Woo HA. Sulfiredoxin, the cysteine sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of action, and biological significance. Kidney Int Suppl 2007;(106):S3-S8.
8. Kwak MK, Wakabayashi N, Greenlaw JL, Yamamoto M, Kensler TW. Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol Cell Biol 2003;23:8786-8794.
9. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 2008;58:262-270.
10. Cho HY, Jedlicka AE, Reddy SP, et al. Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002;26:175-182.
11. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007;47:89-116.
12. Cho HY, Reddy SP, Kleeberger SR. Nrf2 defends the lung from oxidative stress. Antioxid Redox Signal 2006;8:76-87.
13. Colburn NH, Kensler TW. Targeting transcription factors for cancer prevention: the case of Nrf2. Cancer Prev Res (Phila) 2008;1:153-155.
14. Kwak MK, Itoh K, Yamamoto M, Sutter TR, Kensler TW. Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Mol Med 2001;7:135-145.
15. Kwak MK, Itoh K, Yamamoto M, Kensler TW. Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol Cell Biol 2002;22:2883-2892.
16. Osburn WO, Kensler TW. Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res 2008;659:31-39.
17. Park JJ, Chang HW, Jeong EJ, et al. Peroxiredoxin IV protects cells from radiation-induced apoptosis in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2009;73:1196-1202.
18. Stacy DR, Ely K, Massion PP, et al. Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck 2006;28:813-818.
19. Park JH, Kim YS, Lee HL, et al. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology 2006;11:269-275.
20. Bae SH, Woo HA, Sung SH, et al. Induction of sulfiredoxin via an Nrf2-dependent pathway and hyperoxidation of peroxire-doxin III in the lungs of mice exposed to hyperoxia. Antioxid Redox Signal 2009;11:937-948.
21. Findlay VJ, Tapiero H, Townsend DM. Sulfiredoxin: a potential therapeutic agent? Biomed Pharmacother 2005;59:374-379.
22. Jeong W, Park SJ, Chang TS, Lee DY, Rhee SG. Molecular mechanism of the reduction of cysteine sulfinic acid of peroxiredoxin to cysteine by mammalian sulfiredoxin. J Biol Chem 2006;281:14400-14407.
23. Noh YH, Baek JY, Jeong W, Rhee SG, Chang TS. Sulfiredoxin translocation into mitochondria plays a crucial role in reducing hyperoxidized peroxiredoxin III. J Biol Chem 2009;284:8470-8477.
24. Soriano FX, Baxter P, Murray LM, Sporn MB, Gillingwater TH, Hardingham GE. Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin. Mol Cells 2009;27:279-282.
25. Woo HA, Jeong W, Chang TS, et al. Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-cys peroxiredoxins. J Biol Chem 2005;280:3125-3128.
26. Hübner RH, Schwartz JD, De Bishnu P, et al. Coordinate control of expression of Nrf2-modulated genes in the human small airway epithelium is highly responsive to cigarette smoking. Mol Med 2009;15:203-219.
27. Rahman I. Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis 2008;2:351-374.
28. Singh A, Ling G, Suhasini AN, et al. Nrf2-dependent sulfiredox-in-1 expression protects against cigarette smoke-induced oxidative stress in lungs. Free Radic Biol Med 2009;46:376-386.
29. Shibata T, Kokubu A, Gotoh M, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemo-therapy in gallbladder cancer. Gastroenterology 2008;135:1358-1368.